共 50 条
- [1] Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialLANCET, 2023, 402 (10397): : 185 - 195Pal, Sumanta KumarAlbiges, LaurenceTomczak, PiotrSuarez, CristinaVoss, Martin H.de Velasco, GuillermoChahoud, JadMochalova, AnastasiaProcopio, GiuseppeMahammedi, HakimZengerling, FriedemannKim, ChanOsawa, TakahiroAngel, MartinGupta, SuyashaKhan, OmaraBergthold, GuillaumeLiu, BoKalaitzidou, MelaniaHuseni, MahrukhScheffold, ChristianPowles, ThomasChoueiri, Toni K.
- [2] CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Pal, Sumanta K.Albiges, LaurenceRodriguez, Cristina SuarezLiu, BoDoss, JenniferKhurana, SudhaScheffold, ChristianVoss, Martin H.Choueiri, Toni K.
- [3] Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)Choueiri, Toni K.Albiges, LaurenceTomczak, PiotrSuarez, CristinaVoss, Martin H.de Velasco, GuillermoChahoud, JadProcopio, GiuseppeMahammedi, HakimZengerling, FriedemannKim, ChanGupta, SuyashaBergthold, GuillaumeLiu, BoKalaitzidou, MelaniaHuseni, Mahrukh A.Scheffold, ChristianPowles, ThomasPal, Sumanta Kumar
- [4] Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4500 - LBA4500Choueiri, Toni K.Albiges, LaurenceTomczak, PiotrSuarez, CristinaVoss, Martin H.de Velasco, GuillermoChahoud, JadProcopio, GiuseppeMahammedi, HakimZengerling, FriedemannKim, ChanGupta, SuyashaBergthold, GuillaumeLiu, BoKalaitzidou, MelaniaHuseni, Mahrukh A.Scheffold, ChristianPowles, ThomasPal, Sumanta Kumar
- [5] Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2022, 23 (08): : 995 - 1008Kelley, Robin KateRimassa, LorenzaCheng, Ann-LiiKaseb, AhmedQin, ShukuiZhu, Andrew X.Chan, Stephen L.Melkadze, TamarSukeepaisarnjaroen, WattanaBreder, ValeryVerset, GontranGane, EdwardBorbath, IvanRangel, Jose David GomezRyoo, Baek-YeolMakharadze, TamtaMerle, PhilippeBenzaghou, FawziBanerjee, KamalikaHazra, SaswatiFawcett, JonathanYau, Thomas
- [6] Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorCANCER, 2024, 130 (15) : 2621 - 2628Gebrael, GeorgesJo, YeonjungThomas, Vinay MathewLi, HaoranSayegh, NicolasTripathi, NishitaSrivastava, AyanaNordblad, BlakeDal, EmreNarang, ArshitBrundage, JamesCampbell, PatrickFortuna, Gliceida GalarzaChehade, Chadi HageMaughan, Benjamin L.Agarwal, NeerajSwami, Umang
- [7] Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatmentJOURNAL OF HEPATOLOGY, 2024, 81 (02) : 258 - 264Chan, Stephen L.Ryoo, Baek-YeolMo, FrankieChan, Landon L.Cheon, JaekyungLi, LeungWong, Kwan H.Yim, NicoleKim, HyeyeongYoo, Changhoon
- [8] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2016, 17 (07): : 917 - 927Choueiri, Toni K.Escudier, BernardPowles, ThomasTannir, Nizar M.Mainwaring, Paul N.Rini, Brian I.Hammers, Hans J.Donskov, FredeRoth, Bruce J.Peltola, KatriinaLee, Jae LyunHeng, Daniel Y. C.Schmidinger, ManuelaAgarwal, NeerajSternberg, Cora N.McDermott, David F.Aftab, Dana T.Hessel, ColinOld, Christian ScheffSchwab, GiselaHutson, Thomas E.Pal, SumantaMotzer, Robert J.
- [9] A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Verzoni, ElenaBearz, AlessandraDe Giorgi, UgoNole, FrancoPorta, CamilloRatta, RaffaeleClaps, MelaniePagani, FilippoMartinetti, AntoniaCova, AgataRivoltini, LiciaDe Braud, Filippo G.Procopio, Giuseppe
- [10] Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialCLINICAL CANCER RESEARCH, 2022, 28 (08) : 1540 - 1548Meric-Bernstam, FundaTannir, Nizar M.Iliopoulos, OthonLee, Richard J.Telli, Melinda L.Fan, Alice C.DeMichele, AngelaHaas, Naomi B.Patel, Manish R.Harding, James J.Voss, Martin H.Owonikoko, Taofeek K.Carthon, BradleySrinivasan, RamaprasadBendell, Johanna C.Jenkins, YonchuWhiting, Sam H.Orford, KeithBennett, Mark K.Bauer, Todd M.